News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Case Western Reserve University with Copernicus Therapeutics, Inc. and Polgenix Receive $3.9 Million from the Ohio Biomedical Research Commercialization Program (BRCP)


7/1/2008 1:17:31 PM

CLEVELAND--(BUSINESS WIRE)--Case Western Reserve University School of Medicine, in collaboration with Copernicus Therapeutics, Inc. and Polgenix, Inc., was selected to receive $3.9 million in funding from the Ohio Biomedical Research Commercialization Program (BRCP) as awarded by Lieutenant Governor Lee Fisher, Chair of the Ohio Third Frontier Commission.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES